Targets and Emerging Therapies for Schizophrenia (eBook)

Jeffrey S. Albert, Michael W. Wood (Herausgeber)

eBook Download: EPUB

2012 | 1. Auflage
486 Seiten
John Wiley & Sons (Verlag)
978-1-118-30940-7 (ISBN)

Infos

New and emerging directions in pharmaceutical research to
better treat schizophrenia

Although the dopamine hypothesis has been the cornerstone of
schizophrenia therapeutics, it is clear that dopamine-based
approaches do not treat all aspects of the disease. Moreover, many
schizophrenia patients fail to respond to current antipsychotics.
Integrating chemistry, biology, and pharmacology, this book
explores emerging directions in pharmaceutical research for drug
targeting and discovery in order to find more effective treatments
for schizophrenia, one of the most serious and widespread
psychiatric diseases.

Targets and Emerging Therapies for Schizophrenia presents
the basics of schizophrenia, drug targets for the disease, and
potential new drugs and therapeutics. It begins with a discussion
of prevalence and etiology. Then, it describes therapies such as
dopamine agonists and phosphodiesterase (PDE) inhibitors as well as
growing research aimed at addressing untreated symptoms. Next, the
authors discuss receptor modulators, inhibitors, and targeting
strategies for drug discovery. Both the neurobiological and
chemical aspects of all major pharmacological targets are
examined.

With contributions from an international team of pioneering
pharmaceutical researchers, this book compiles the current
knowledge in the field, setting the stage for new breakthroughs in
the treatment of schizophrenia. Targets and Emerging Therapies
for Schizophrenia:

* Provides a comprehensive resource for neuro-drug discovery and
the development of molecular targets for schizophrenia
treatment

* Draws from chemistry, biology, and pharmacology for more
effective drug targeting and discovery

* Explores a wide range of receptors and molecular targets,
including dopamine, PDEs, and neuropeptides

With Targets and Emerging Therapies for Schizophrenia as
their guide, drug discovery and development scientists have the
information they need to advance their own research so that new,
more effective treatments for schizophrenia will soon be a
reality.

Autor

JEFFREY S. ALBERT, PhD, is a Project Leader and Head of Lead Generation Chemistry in AstraZeneca's neuroscience department. He has authored or coauthored more than forty publications, mostly focusing on novel therapeutic targets involved in depression, schizophrenia, and Alzheimer's disease and on the development and application of fragment-based lead generation methodologies. MICHAEL W. WOOD, PhD, is an External Collaborations Director in AstraZeneca's neuroscience unit where he is responsible for coordinating research to deliver novel therapeutics targeting schizophrenia as well as other neuroscience treatments. He has been focused on neuroscience drug discovery research for fifteen years.

Inhalt

Preface vii

Contributors xi

Introduction 1

Alan J. Cross

1 Dopaminergic Hypothesis of Schizophrenia: A Historical
Perspective 5

Aurelija Jucaite and Svante Nyberg

2 Dopamine D2/D3 Partial Agonists as Antipsychotics 37

Philip G. Strange

3 D1/D5 Dopamine Agonists as Pharmacotherapy for Schizophrenia
51

Kevin N. Boyd and Richard B. Mailman

4 Phosphodiesterase Inhibitors as a Novel Therapeutic Approach
for Schizophrenia 85

Judith A. Siuciak and William J. Pitts

5 Glutamatergic Synaptic Dysregulation in Schizophrenia
115

Joseph T. Coyle, Alo Basu, and Michael Benneyworth

6 Metabotropic Glutamate 2/3 Receptor Agonists and Positive
Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel
Agents for the Treatment of Schizophrenia 143

Gerard J. Marek, Bruce J. Kinon, David L. McKinzie, Jeffrey M.
Schkeryantz, and James A. Monn

7 AMPA Receptor Positive Modulators 187

John A. Morrow, John K.F. Maclean, and Craig Jamieson

8 Progress in the Exploration and Development of GlyT1
Inhibitors for Schizophrenia 233

Jeffrey S. Albert and Michael W. Wood

9 Combined Dopamine D2 and 5-Hydroxytryptamine (5-HT)1A Receptor
Strategies for the Treatment of Schizophrenia: A Pharmacological
and Chemical Perspective 255

Andrew C. McCreary, Roelof W. Feenstra, and Caitlin A.
Jones

10 5-HT2C and 5-HT6 Receptor Targeted Emerging Approaches in
Schizophrenia 273

Sharon Rosenzweig-Lipson, John Dunlop, Lee E. Schechter, Thomas
A. Comery, Jonathan Gross, and Karen L. Marquis

11 The Cholinergic Hypothesis: An Introduction to the Hypothesis
and a Short History 295

Joseph I. Friedman, Isabella Kanellopoulou, and Vladan
Novakovic

12 alpha7 Nicotinic Acetylcholine Receptors in the Treatment of
Schizophrenia 319

Mihály Hajós and Bruce N. Rogers

13 Muscarinic Acetylcholine Receptors as Novel Targets for the
Development of Therapeutics for Schizophrenia 355

Christian C. Felder, David L. McKinzie, Richard C. Thompson, and
Bin Liu

14 Will Modulation of Neuropeptide Receptors Produce the Next
Generation of Antipsychotic Drugs? A Focus on the Neurokinin and
Neurotensin Systems 381

Lee A. Dawson, Paul W. Smith, and Jeannette M. Watson

15 GABA and Schizophrenia 425

John H. Kehne and George D. Maynard

Index 469

Rezensionen

"In summary, this book provides a timely and convenient
reflection on schizophrenia drug discovery and development, which
has been a major component of psychiatric drug research for several
decades." (ChemMedChem, 1 March 2013)

Produkt-Details

• Erscheint lt. Verlag: 6.6.2012
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Gesundheitsfachberufe
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete
• Themenwelt: Naturwissenschaften ► Biologie
• Themenwelt: Naturwissenschaften ► Chemie
• Schlagworte: Biowissenschaften • Chemie • Chemistry • Drug Discovery & Development • Life Sciences • Medical Science • Medizin • Neuroscience • Neurowissenschaften • Pharmacology & Pharmaceutical Medicine • Pharmakologie u. Pharmazeutische Medizin • Schizophrenie • Wirkstoffforschung • Wirkstoffforschung u. -entwicklung
• ISBN-10: 1-118-30940-5 / 1118309405
• ISBN-13: 978-1-118-30940-7 / 9781118309407